Sort
130,381 grants matching “hiv”
Therapeutic Strategies for the Management of HCV/HIV co- infection
$1,076,509Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Scientific Project One
$1,076,473Leonidas A Stamatatos · Fred Hutchinson Cancer Center · U19 · FY2023 · AI
Role of Memory T Cell Dynamics in SIV Infection
$1,076,069Louis J. Picker · Oregon Health & Science University · R37 · FY2009 · AI
Immunity to novel T/F SHIVs: variability in the co-evolution of virus and host immunity
$1,075,751Garnett H Kelsoe · Duke University · R01 · FY2017 · AI
HIV-1 RNase H as a Therapeutic Target
$1,075,719Stuart F. J. Le Grice · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Towards Treatment of Alzheimerâs Disease by Targeting Pathogenic Tau and Beta-Amyloid Structures
$1,075,649David Eisenberg · University Of California Los Angeles · R56 · FY2021 · AG
Virus biology scientific research support component
$1,075,630Beatrice H Hahn · Duke University · UM1 · FY2017 · AI
Administrative Core
$1,075,604Shan Lu · Univ Of Massachusetts Med Sch Worcester · U19 · FY2012 · AI
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$1,075,525Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
HIV-1 subtype, specific drug resistance in patients failing Dolutegravir-based 1st, 2nd or 3rd line regimens: the International epidemiological Databases to Evaluate AIDS (IeDEA)
$1,075,525Matthias Egger · Universitat Bern · R01 · FY2022 · AI
Fibrotic Sequelae of Childhood Renal Disease
$1,075,382Vanderbilt University · P50 · FY2002 · DK
DRW HIV-Ab/HCV-Ab/HBsAg Triplex Rapid Test Submission for FDA-PMA Approval
$1,075,162Helen H Lee · Diagnostics For The Real World, Ltd · R44 · FY2010 · HL
HIVAN II
$1,075,077Gale Newman · Morehouse School Of Medicine · U54 · FY2010 · RR
GH11-1152, PLANNING, IMPLEMENTATON, EVALUATION OF COMPREHENSIVE HIV PREV
$1,075,000Harry Peter Hausler · Tb Hiv Care · U2G · FY2014 · GH
Molecular profile of proviral reservoirs in HIV-infected drug users
$1,074,970Xu Yu · Massachusetts General Hospital · R61 · FY2020 · DA
pH Responsive anti-HIV Nanoparticles
$1,074,963Rodney J.y. Ho · University Of Washington · R01 · FY2013 · AI
HIV Prevention Trials Network: Network Laboratory
$1,074,961Susan H Eshleman · Johns Hopkins University · UM1 · FY2013 · AI
EXTENSION OF ABAN AYA YOUTH PROJECT
$1,074,916University Of Illinois At Chicago · R01 · FY2002 · DA
Recipient Epidemiology and Donor Evaluation Study III (REDS-III) Domestic Hub
$1,074,774Edward Murphy · University Of California, San Francisco · N01 · FY2014 · HL
Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects
$1,074,746Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Models of SBIRT for Opioid Dependent Patients in the Emergency Department
$1,074,638Gail D'onofrio · Yale University · R01 · FY2009 · DA
Staged Low-Barrier and Mobile Care to Improve Retention and Viral Suppression in Hard-To-Reach Vulnerable People Living With HIV
$1,074,602Katerina A Christopoulos · University Of California, San Francisco · R01 · FY2023 · AI
DRUG USERS IN NEW YORK AND PUERTO RICO--HIV RISK BEHAVIO
$1,074,516National Development &Res Institutes · R01 · FY2001 · DA
Project 1: PREVENT Program Critical Path Project
$1,074,483Daniel Tuse · University Of Louisville · U19 · FY2017 · AI
Factors Influencing Genetic Transcription Initiation And Termination
$1,074,437Robert J Crouch · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2016 · HD